Bhringaraj

Eclipta prostrata (Bhringaraj) is primarily used for hepatoprotection, with wedelolactone and demethylwedelolactone shown to reduce transaminase elevation, attenuate immune-mediated liver injury (via TNF-alpha and IFN-gamma suppression in ConA-induced hepatitis models), and protect against CCl4-induced oxidative hepatotoxicity. When combined with hepatotoxic drugs, Bhringaraj may mask hepatotoxicity signals by suppressing transaminase elevation and anti-inflammatory markers, potentially delaying detection of drug-induced liver injury. Conversely, it may provide genuine hepatoprotection.

Monitor liver function tests (ALT, AST, bilirubin) at baseline and periodically when combining Bhringaraj with potentially hepatotoxic drugs. Be aware that wedelolactone may suppress transaminase elevation, masking early DILI signals. Do not rely solely on transaminase monitoring — assess clinical symptoms as well. Discuss with hepatologist in high-risk patients.

Eclipta prostrata has been reported to modulate coagulation pathways in preclinical studies. Wedelolactone has demonstrated mild antiplatelet activity. Ayurvedic and traditional sources flag mild clotting modulation as a potential concern. The herb is classified as having mild blood-thinning properties in some traditional medicine systems. When combined with anticoagulants, additive anticoagulant effects could increase bleeding risk.

Monitor INR if patients on warfarin use Bhringaraj preparations. Advise patients with bleeding disorders or on anticoagulants to consult their healthcare provider before using Bhringaraj. Discontinue at least 2 weeks before elective surgery. Observe for signs of unusual bleeding (bruising, prolonged wound bleeding, blood in stool/urine).

Eclipta prostrata has demonstrated hypoglycemic activity in alloxan-induced diabetic rats, with significant blood glucose reduction attributed to multiple constituent classes (flavonoids, steroids, triterpenes). Network pharmacology analyses identify AGE-RAGE signaling in diabetic complications and metabolic pathways as key targets. Additive hypoglycemic effects when combined with antidiabetic drugs may cause hypoglycemia, particularly with insulin or sulfonylureas.

Monitor blood glucose more frequently when Bhringaraj preparations are used alongside antidiabetic medications. Educate patients on hypoglycaemia symptoms. Consider dose reduction of sulfonylurea under medical supervision. This combination may be useful in metabolic syndrome management but requires monitoring.

Wedelolactone (a coumestan in Eclipta prostrata) has been shown to modulate P-glycoprotein (P-gp) expression and function, potentially affecting drug resistance in chemotherapy. Topoisomerase II inhibition by wedelolactone has also been documented, which could theoretically interact with etoposide and doxorubicin. While some interactions may be beneficial (reversing MDR), the net effect is uncertain and could increase chemotherapy toxicity or reduce efficacy.

Bhringaraj use during cancer chemotherapy should be disclosed to the oncology team. Do not use high-dose preparations alongside chemotherapy without oncological guidance. Monitor for unexpected changes in chemotherapy toxicity profile or treatment response. The potential for P-gp modulation affecting drug efflux is clinically significant.

Eclipta prostrata possesses immunomodulatory activity, including activation of macrophages, enhancement of NK cell activity, and modulation of T-cell responses. These immunostimulatory effects may partially counteract immunosuppressive drugs. In patients requiring suppression of immune activity (transplant, autoimmune disease), Bhringaraj could potentially reduce drug efficacy. The herb is also used to support liver function after hepatotoxic treatments.

Use with caution in patients on immunosuppressive therapy. Monitor for breakthrough inflammation or graft rejection in transplant patients. Disclose Bhringaraj use to supervising physician. Benefits for liver health in patients on immunosuppressants may be significant, but the risk-benefit ratio should be evaluated individually.